Polaris Venture Management Co. V L.L.C. Acquires New Position in Selecta Biosciences Inc. (SELB)
Polaris Venture Management Co. V L.L.C. acquired a new stake in shares of Selecta Biosciences Inc. (NASDAQ:SELB) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 1,924,151 shares of the company’s stock, valued at approximately $26,919,000. Selecta Biosciences comprises 28.9% of Polaris Venture Management Co. V L.L.C.’s holdings, making the stock its largest position.
Shares of Selecta Biosciences Inc. (NASDAQ:SELB) traded up 1.30% during midday trading on Friday, reaching $16.42. The company’s stock had a trading volume of 1,845 shares. The company has a 50 day moving average of $13.97 and a 200-day moving average of $13.35. Selecta Biosciences Inc. has a 52 week low of $10.26 and a 52 week high of $18.88.
SELB has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Selecta Biosciences from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Tuesday, September 20th. Needham & Company LLC began coverage on Selecta Biosciences in a research note on Monday, July 18th. They issued a “buy” rating and a $28.00 target price for the company. Canaccord Genuity began coverage on Selecta Biosciences in a research report on Monday, July 18th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Stifel Nicolaus began coverage on Selecta Biosciences in a research report on Monday, July 18th. They set a “buy” rating and a $23.00 price target on the stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.
Receive News & Stock Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related stocks with our FREE daily email newsletter.